Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Andre Goy; Anas Younes; Peter McLaughlin; Barbara Pro; Jorge E Romaguera; Frederick Hagemeister; Luis Fayad; Nam H Dang; Felipe Samaniego; Michael Wang

doi:10.1200/JCO.2005.03.108

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Identifier:nobleid.org/w1/20260515/A2ABC597

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/A2ABC597.svg?ark=w1%2F20260515%2FA2ABC597)](https://nobleid.org/work/w1/20260515/A2ABC597)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Frederick Hagemeister

Claim authorship of this work

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Identifier:nobleid.org/w1/20260515/A2ABC597

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/A2ABC597.svg?ark=w1%2F20260515%2FA2ABC597)](https://nobleid.org/work/w1/20260515/A2ABC597)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Frederick Hagemeister

Claim authorship of this work